Awardee OrganizationUNIVERSITY OF CALIFORNIA LOS ANGELES
Description
Abstract Text
DESCRIPTION (provided by applicant): Thyroid hormone is essential for the regulation of a range of processes including neural development, bone development, somatic growth, cardiac function, and metabolism. The regulation of thyroid hormone action is accomplished through tight control of thyroid hormone production by the hypothalamic-pituitary-thyroid axis, local and systemic activation and inactivation of thyroid hormone by deiodinase enzymes, and differential expression of thyroid hormone receptor (TR) isoforms in target tissues. A variety of animal models, and observations from humans with deficits of thyroid hormone action, have identified specific roles for thyroid hormone receptor isoforms. Many actions of thyroid hormone can be mediated by either TRalpha or beta, but others are quite specific for one TR isoform. TR isoform-specific actions have been identified in the brain, developing ear, retina, pituitary, heart, liver, and in brown adipose tissue (BAT). This proposal will utilize genetic models and pharmacological agents to identify and study the mechanism of TR isoform-specific actions in metabolism, adaptive thermogenesis, and cardiac function. The proposed studies will especially focus on the integration of thyroid-mediated signals in metabolic control with actions in white adipose tissue (WAT), BAT, liver, and heart. The importance of TRalpha in adrenergic signaling is demonstrated by our TRalphaP398H mutant mouse, with the phenotype of visceral obesity, insulin resistance, fatty liver, defective adaptive thermogenesis, and a marked deficit of catecholamine-mediated lipolysis in WAT. The specific aims of this study include; (1) To characterize the role ofTRalpha and beta in metabolic regulation in WAT and BAT, focusing on the action of TRalpha in mediating catecholamine sensitivity, (2) To characterize the metabolic phenotype in TRalphaP398H mutant mice including; serum lipoprotein profile, hepatic gene expression, body fat composition, insulin sensitivity, and response to changes in thyroid status, gonadal status and with PPARalpha and gamma agonist treatment, (3) To characterize the role of TRalpha in cardiac function and gene expression, including dynamic effects of exercise and the short and long-term influence of catecholamines on the heart, (4) To utilize in vitro models to determine the mechanisms of TRalpha -specific gene regulation and especially the influence of the TRalpha dominant negative mutations on gene regulation. The results of these studies will provide important insights into the role of TR in metabolic signaling, with implications for understanding underlying mechanisms and developing novel treatments for obesity, insulin resistance, and cardiovascular disease.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
092530369
UEI
RN64EPNH8JC6
Project Start Date
01-March-2004
Project End Date
28-February-2009
Budget Start Date
01-March-2005
Budget End Date
28-February-2006
Project Funding Information for 2005
Total Funding
$289,800
Direct Costs
$230,000
Indirect Costs
$59,800
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Diabetes and Digestive and Kidney Diseases
$289,800
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DK067233-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DK067233-02
Patents
No Patents information available for 5R01DK067233-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DK067233-02
Clinical Studies
No Clinical Studies information available for 5R01DK067233-02
News and More
Related News Releases
No news release information available for 5R01DK067233-02
History
No Historical information available for 5R01DK067233-02
Similar Projects
No Similar Projects information available for 5R01DK067233-02